In an aggressive disease known for poor response rates, researchers found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.
http://ift.tt/1pyns5L
http://ift.tt/1pyns5L
No comments:
Post a Comment